Online citations, reference lists, and bibliographies.
← Back to Search

The American College Of Rheumatology Preliminary Core Set Of Disease Activity Measures For Rheumatoid Arthritis Clinical Trials. The Committee On Outcome Measures In Rheumatoid Arthritis Clinical Trials.

D. Felson, J. Anderson, M. Boers, C. Bombardier, M. Chernoff, B. Fried, D. Furst, C. Goldsmith, S. Kieszak, R. Lightfoot
Published 1993 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
OBJECTIVE To develop a set of disease activity measures for use in rheumatoid arthritis (RA) clinical trials, as well as to recommend specific methods for assessing each outcome measure. This is not intended to be a restrictive list, but rather, a core set of measures that should be included in all trials. METHODS We evaluated disease activity measures commonly used in RA trials, to determine which measures best met each of 5 types of validity: construct, face, content, criterion, and discriminant. The evaluation consisted of an initial structured review of the literature on the validity of measures, with an analysis of data obtained from clinical trials to fill in gaps in this literature. A committee of experts in clinical trials, health services research, and biostatistics reviewed the validity data. A nominal group process method was used to reach consensus on a core set of disease activity measures. This set was then reviewed and finalized at an international conference on outcome measures for RA clinical trials. The committee also selected specific ways to assess each outcome. RESULTS The core set of disease activity measures consists of a tender joint count, swollen joint count, patient's assessment of pain, patient's and physician's global assessments of disease activity, patient's assessment of physical function, and laboratory evaluation of 1 acute-phase reactant. Together, these measures sample the broad range of improvement in RA (have content validity), and all are at least moderately sensitive to change (have discriminant validity). Many of them predict other important long-term outcomes in RA, including physical disability, radiographic damage, and death. Other disease activity measures frequently used in clinical trials were not chosen for any one of several reasons, including insensitivity to change or duplication of information provided by one of the core measures (e.g., tender joint score and tender joint count). The committee also proposes specific ways of measuring each outcome. CONCLUSION We propose a core set of outcome measures for RA clinical trials. We hope this will decrease the number of outcomes assessed and standardize outcomes assessments. Further, we hope that these measures will be found useful in long-term studies.
This paper references
A Seven‐Day variability study of 499 patients with peripheral rheumatoid arthritis
D. Mainland (1965)
Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis.
D. Ritchie (1968)
The Effectiveness of Nominal, Delphi, and Interacting Group Decision Making Processes
A. V. D. Ven (1974)
Group Techniques for Program Planning: A Guide to Nominal Group and Delphi Processes
André L. Delbecq (1976)
T. T. Herbert (1979)
Measuring health status in arthritis. The arthritis impact measurement scales.
R. Meenan (1980)
Increased mortality among persons with rheumatoid arthritis, but where RA does not appear on death certificate. Eleven-year follow-up of an epidemiological study.
P. Allebeck (1981)
Cause and age at death in a prospective study of 100 patients with rheumatoid arthritis.
J. Rasker (1981)
An Empirical Test of the Nominal Group Technique in State Solar Energy Planning
Blair Y. Stephenson (1982)
The McMaster Health Index Questionnaire as a measure of quality of life for patients with rheumatoid disease.
L. Chambers (1982)
A methodologic framework for developing and selecting endpoints in clinical trials.
P. Tugwell (1982)
Outcome assessment in clinical trials. Evidence for the sensitivity of a health status measure.
R. Meenan (1984)
Problems associated with pain measurement in arthritis: comparison of the visual analogue and verbal rating scales.
G. Langley (1984)
Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years.
T. Pincus (1984)
Reduced joint count indices in the evaluation of rheumatoid arthritis.
M. Egger (1985)
Anti-rheumatic drugs and joint damage in rheumatoid arthritis.
D. Scott (1985)
Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression.
P. Dawes (1986)
Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial.
C. Bombardier (1986)
Survival, prognosis, and causes of death in rheumatoid arthritis.
D. Mitchell (1986)
The MACTAR Patient Preference Disability Questionnaire--an individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis.
P. Tugwell (1987)
Questionnaire, walking time and button test measures of functional capacity as predictive markers for mortality in rheumatoid arthritis.
T. Pincus (1987)
What are we measuring? An examination of walk time and grip strength.
J. S. Spiegel (1987)
Radiographic and joint count findings of the hand in rheumatoid arthritis. Related and unrelated findings.
H. Fuchs (1988)
What are the 'best' measurements for monitoring patients during short-term second-line therapy?
J. Dixon (1988)
Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis.
T. Möttönen (1988)
An experiment in reducing interobserver variability of the examination for joint tenderness.
A. Klinkhoff (1988)
Two double blind trials of diclofenac sodium with aspirin and with naproxen in the treatment of patients with rheumatoid arthritis.
Kolodny Al (1988)
The role of evidence in the consensus process. Results from a Canadian consensus exercise.
J. Lomas (1988)
Influence of prognostic features on the final outcome in rheumatoid arthritis: a review of the literature.
D. Heijde (1988)
Sensitivity of a health status measure to short-term clinical changes in arthritis.
J. Anderson (1989)
Which traditional measures should be used in rheumatoid arthritis clinical trials?
J. Anderson (1989)
What should we hope to achieve when treating rheumatoid arthritis?
D. Scott (1989)
B. Bull (1989)
Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures.
T. Pincus (1989)
Health status as a predictor of mortality in rheumatoid arthritis: a five-year study.
L. Kazis (1990)
Sensitivity of a Dutch Health Assessment Questionnaire in a Trial Comparing Hydroxychloroquine vs. Sulphasalazine
D. V. D. Heijde (1990)
Sensitivity of effect variables in rheumatoid arthritis: A meta-analysis of 130 placebo controlled NSAID trials controlled NSAID trials
Peter C. G∅tzsche (1990)
Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnaires.
P. Tugwell (1990)
Rheumatoid arthritis antirheumatic drug trials. I. Effects of standardization procedures on observer dependent outcome measures.
N. Bellamy (1991)
The latex test revisited. Rheumatoid factor testing in 8,287 rheumatic disease patients.
F. Wolfe (1991)
Mortality predictors among 263 patients with rheumatoid arthritis.
J. Leigh (1991)
Comparison of four articular indices for use in clinical trials in rheumatoid arthritis: patient, order and observer variation.
P. Thompson (1991)
The total hip arthroplasty outcome evaluation form of the American Academy of Orthopaedic Surgeons. Results of a nominal group process. The American Academy of Orthopaedic Surgeons Task Force on Outcome Studies.
M. Liang (1991)
A comparison of health-related quality-of-life measures for rheumatoid arthritis research. The Auranofin Cooperating Group.
C. Bombardier (1991)
The assessment and prediction of functional disability in rheumatoid arthritis.
F. Wolfe (1991)
Clinical and health status measures over time: prognosis and outcome assessment in rheumatoid arthritis.
F. Wolfe (1991)
Suppression of type II collagen-induced arthritis by monoclonal antibodies.
S. Kobayashi (1991)
Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis.
D. V. D. Heijde (1992)
Can out‐of‐hours work by junior doctors in obstetrics be reduced?
M. Mckee (1992)
Predictors of disability in a longitudinal sample of patients with rheumatoid arthritis.
J. Leigh (1992)
Classification of antirheumatic drugs. A new proposal.
H. Paulus (1992)
Sensitivity to change of the health assessment questionnaire (HAQ) and other clinical and health status measures in rheumatoid arthritis: results of short-term clinical trials and observational studies versus long-term observational studies.
D. Hawley (1992)
The impact of endpoint measures in rheumatoid arthritis clinical trials.
A. van der Heide (1992)

This paper is referenced by
Increased disease activity in early arthritis patients with anti-carbamylated protein antibodies
C. Regueiro (2021)
Network meta-analysis of infliximab biosimilars for the treatment of rheumatoid arthritis
Conor Hanrahan (2021)
Current status and influencing factors of fatigue in patients with rheumatoid arthritis: A cross-sectional study in China.
Lei Gao (2021)
Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials
B. Combe (2021)
Validation of a Spanish version of the Health Assessment Questionnaire-II to assess Mexican patients' physical function with rheumatoid arthritis.
G. Horta-Baas (2021)
OPEX: Development of a novel overall patient experience measure to facilitate interpretation of comparison effectiveness studies
L. Fraenkel (2021)
Use of Patient and Investigator Global Impression Scales: A Review of Food and Drug Administration-Approved Labeling, 2009 to 2019.
A. Gnanasakthy (2021)
Biological Therapy in Patients with Rheumatoid Arthritis in a Tertiary Center in Portugal: A Cross-Sectional Study.
M. Fernandes (2021)
Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan
T. Takeuchi (2021)
Associations of ultrasound-based inflammation patterns with peripheral innate lymphoid cell populations, serum cytokines/chemokines, and treatment response to methotrexate in rheumatoid arthritis and spondyloarthritis
Manami Kato (2021)
Effect of interleukin-17A inhibitor in Japanese patients with psoriatic arthritis compared with tumor necrosis factor-alpha inhibitor
T. Izumiyama (2021)
Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study
Yue Yang (2021)
Summarizing current refractory disease definitions in rheumatoid arthritis and polyarticular juvenile idiopathic arthritis: systematic review
H. Chaplin (2021)
Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis
Yoshiya Tanaka (2021)
Quantification of morning stiffness to assess disease activity and treatment effects in rheumatoid arthritis.
H. Boeth (2021)
Which patient-reported outcomes do rheumatology patients find important to track digitally? A real-world longitudinal study in ArthritisPower
W. Nowell (2021)
Влияние олокизумаба на исходы, оцениваемые пациентом с ревматоидным артритом: результаты двойного слепого рандомизированного плацебо-контролируемого многоцентрового исследования III фазы (CREDO 1)
Евгений Львович Насонов (2021)
Response Similarity Assessment Between Polyarticular Juvenile Idiopathic Arthritis and Adult Rheumatoid Arthritis for Biologics
Renu F. Singh (2021)
Sequential knockoffs for continuous and categorical predictors: With application to a large psoriatic arthritis clinical trial pool.
Matthias Kormaksson (2021)
Estimation of Disease Activity in Rheumatoid Arthritis: A Correlation Study between Clinical, Inflammatory Markers and Power Doppler Ultrasonography
T. Sarkar (2020)
Measuring outcomes in trials of interventions for people who self-harm: qualitative study of service users' views
C. Owens (2020)
Pharmacological conditioning in the treatment of recent-onset rheumatoid arthritis: a randomized controlled trial study protocol
M. Manaï (2020)
Methods used in the selection of instruments for outcomes included in Core Outcome Sets have improved since the publication of the COSMIN/COMET guideline.
S. Gorst (2020)
Biologic therapies for systemic lupus erythematosus: where are we now?
G. Murphy (2020)
Health Disparities AmongHispanicsWith Rheumatoid Arthritis Delay in Presentation to Rheumatologists Contributes to Later Diagnosis and Treatment
Mariam Riad (2020)
Biosimilar Drug Development
J. Mielke (2020)
When the first visit to the rheumatologist is established rheumatoid arthritis.
P. Taylor (2020)
Developing Smartphone-Based Objective Assessments of Physical Function in Rheumatoid Arthritis Patients: The PARADE Study
Valentin Hamy (2020)
Outcomes Reported in Prospective Long‐Term Observational Studies and Registries of Patients With Rheumatoid Arthritis Worldwide: An Outcome Measures in Rheumatology Systematic Review
M. Lopez‐Olivo (2020)
Disease activity trajectories in rheumatoid arthritis: a tool for prediction of outcome
M. Leu Agelii (2020)
Cumulative patient-based disease activity monitoring in rheumatoid arthritis - predicts sustained remission, flare and treatment escalation.
M. Leung (2020)
A multicenter, randomized, double-blind, placebo- controlled trial evaluating the efficacy and safety of Huang
Qi Gui (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar